Benjamin Palleiko Sells 3,354 Shares of KalVista Pharmaceuticals (NASDAQ:KALV) Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin Palleiko sold 3,354 shares of the business’s stock in a transaction dated Thursday, February 12th. The stock was sold at an average price of $15.70, for a total transaction of $52,657.80. Following the sale, the chief executive officer directly owned 428,286 shares of the company’s stock, valued at $6,724,090.20. This represents a 0.78% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

KalVista Pharmaceuticals Price Performance

NASDAQ KALV traded down $0.21 during mid-day trading on Friday, hitting $14.91. The stock had a trading volume of 499,248 shares, compared to its average volume of 1,104,665. KalVista Pharmaceuticals, Inc. has a twelve month low of $9.23 and a twelve month high of $19.00. The stock has a market capitalization of $753.70 million, a price-to-earnings ratio of -3.77 and a beta of -0.19. The firm’s 50 day moving average is $15.66 and its 200 day moving average is $13.81. The company has a debt-to-equity ratio of 8.18, a current ratio of 7.22 and a quick ratio of 7.21.

KalVista Pharmaceuticals (NASDAQ:KALV) last released its earnings results on Monday, November 10th. The specialty pharmaceutical company reported ($0.92) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.96) by $0.04. The business had revenue of $13.69 million during the quarter, compared to analysts’ expectations of $6.03 million. Equities research analysts forecast that KalVista Pharmaceuticals, Inc. will post -3.56 earnings per share for the current fiscal year.

Institutional Investors Weigh In On KalVista Pharmaceuticals

Institutional investors have recently modified their holdings of the company. Tudor Investment Corp ET AL purchased a new position in KalVista Pharmaceuticals during the 3rd quarter valued at about $24,360,000. Parkman Healthcare Partners LLC lifted its position in shares of KalVista Pharmaceuticals by 155.5% during the third quarter. Parkman Healthcare Partners LLC now owns 1,735,003 shares of the specialty pharmaceutical company’s stock worth $21,132,000 after purchasing an additional 1,055,940 shares in the last quarter. Ameriprise Financial Inc. grew its holdings in shares of KalVista Pharmaceuticals by 2,258.6% in the second quarter. Ameriprise Financial Inc. now owns 945,125 shares of the specialty pharmaceutical company’s stock valued at $10,685,000 after purchasing an additional 905,053 shares in the last quarter. Freestone Grove Partners LP purchased a new stake in KalVista Pharmaceuticals during the 3rd quarter worth approximately $8,580,000. Finally, Schroder Investment Management Group grew its stake in shares of KalVista Pharmaceuticals by 108.7% in the third quarter. Schroder Investment Management Group now owns 1,158,457 shares of the specialty pharmaceutical company’s stock worth $14,145,000 after acquiring an additional 603,499 shares in the last quarter.

Analysts Set New Price Targets

Several research analysts have recently commented on KALV shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a report on Thursday, January 22nd. HC Wainwright lifted their target price on shares of KalVista Pharmaceuticals from $27.00 to $37.00 and gave the stock a “buy” rating in a research note on Friday, January 9th. Citigroup reiterated a “market outperform” rating on shares of KalVista Pharmaceuticals in a report on Tuesday, November 11th. TD Cowen restated a “buy” rating on shares of KalVista Pharmaceuticals in a report on Wednesday, December 3rd. Finally, Wall Street Zen upgraded KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, December 6th. Eight investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $29.17.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.